Phase 2 Asthma Trial, Recruiting NCT06372249 Sponsor: Phoenix Children's Hospital Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT06372249
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and teenagers between the ages of 6 and 17
  • People who have been diagnosed with asthma within the last 2 years
  • People who have either a breath test result showing airway inflammation above a certain level (FeNO greater than 50 ppb), or a confirmed history of environmental allergies shown by a skin prick test or a blood test for allergen sensitivity
  • People who have not visited an emergency department in the past month
  • People who are able to drink a liquid containing fiber or a placebo (inactive substitute)
  • People who are able to return for a follow-up visit 4 to 6 weeks after joining
  • People who do not follow a special or restricted diet

Who may not be able to join:

  • People who have cystic fibrosis
  • People who have bronchiectasis (a long-term lung condition affecting the airways)
  • People whose asthma medications (other than quick-relief inhalers) are planned to change during the 4 to 6 week study period
  • People whose estimated daily fiber intake is 16 grams or less, as measured by a specific dietary recall tool called the ASA24
  • People who have a sibling already enrolled in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Matthew Rank, Phoenix Children's

Phone: 6029334979

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Phoenix Children's Hospital
Registry
ClinicalTrials.gov
Start date
10 November 2025
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Alpha diversity.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov